Yiwei Liu

Senior Research Scientist

Share
Share

Start Year

2021

Developing antibody therapeutics for T cell-acute lymphoblastic leukemia (T-ALL)

Despite successes in developing effective immunotherapy for B-ALL, little progress has been made for T-ALL. New targets which distinguish T-ALL blasts and normal T lymphocytes need to be identified and novel immunotherapy agents developed for this type of ALL.

My previous work includes high molecular weight polyethylene glycol (PEG) and anti-PEG antibodies in hypersensitivity reactions to pegaspargase, liposome-conjugated PEG, and unconjugated PEG; pegaspargase pharmacokinetics; age-dependent hepatotoxicity of pegaspargase; pharmacogenomics of chemotherapy-induced toxicity in pediatric leukemia.